SCHEMBL4037595

SCHEMBL4037595

CCOC(=O)c1coc(-c2cn(CC(C)C)c3ccc(C)cc23)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ICMT O60725 4/20 0.39
POLB P06746 2/20 0.39
KDM4E B2RXH2 2/20 0.39
ELANE P08246 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.35
GABRA2 P47869 2/20 0.34
GABRB2 P47870 2/20 0.34
MAPK1 P28482 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
NR1H2 P55055 1/20 0.34
CYP1A2 P05177 1/20 0.34
GABRP O00591 1/20 0.34
GABRD O14764 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRB1 P18505 1/20 0.34
GABRG2 P18507 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3596646 0.90 ALDH1A1 (0.44) KDM4EELANEGABRA2GABRB2HPGD
SCHEMBL4037157 0.88 ICMT (0.41) ICMT
SCHEMBL4350902 0.82 ALDH1A1 (0.43) KDM4EELANEGABRA2GABRB2HPGD
SCHEMBL4348472 0.79 PTGS2 (0.39) ICMTPOLBKDM4EMAPT
SCHEMBL3595139 0.77 PTGER1 (0.41) ICMT
SCHEMBL3594920 0.77 PTGER1 (0.41) ICMTMAPT
SCHEMBL4357086 0.77 ALDH1A1 (0.43) KDM4EELANEGABRA2GABRB2HPGD
SCHEMBL4357082 0.76 ALDH1A1 (0.41) KDM4EELANEGABRA2GABRB2HPGD
SCHEMBL3592829 0.76 ICMT (0.41) ICMTKDM4E
SCHEMBL3588519 0.76 CNR1 (0.44) KDM4EELANEGABRA2GABRB2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090281152-A1 Indole Compounds Having Affinity to the EP1 Receptor GLAXO GROUP LIMITED (GB) 2009-11-12 US disclosed
US-20090281152-A1 Indole Compounds Having Affinity to the EP1 Receptor GLAXO GROUP LIMITED (GB) 2009-11-12 US disclosed
US-20090281152-A1 Indole Compounds Having Affinity to the EP1 Receptor GLAXO GROUP LIMITED (GB) 2009-11-12 US disclosed
EP-2041126-A1 INDOLE COMPOUNDS HAVING AFFINITY TO THE EP1 RECEPTOR Glaxo Group Limited (GB) 2009-04-01 EP disclosed
WO-2008006794-A1 INDOLE COMPOUNDS HAVING AFFINITY TO THE EP1 RECEPTOR GLAXO GROUP LIMITED (GB) 2008-01-17 WO disclosed
WO-2008006794-A1 INDOLE COMPOUNDS HAVING AFFINITY TO THE EP1 RECEPTOR GLAXO GROUP LIMITED (GB) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281152-A1 Indole Compounds Having Affinity to the EP1 Receptor PTGER1, PTGER2, PTGER3 ICMT 946/4885POLB 4787/4885KDM4E 2597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.